Myriad Genetics (MYGN) Q2 2026: Revenue Falls 11% as Payer Friction Pressures Hereditary Cancer Testing
Payer-driven reimbursement friction and a sharp decline in prenatal volumes drove Myriad Genetics’ Q2 revenue down, forcing a guidance cut and suspended EBITDA outlook. Management is prioritizing operational overhaul and portfolio focus, but near-term profit visibility remains clouded by persistent headwinds in hereditary cancer test reimbursement. Investors should watch for execution on cost initiatives and commercial launches to restore predictability.
Summary
- Payer Friction Disrupts Revenue: Aggressive reimbursement denials from select payers sharply reduced average revenue per test.
- Operational Restructuring Underway: Company launched the ASCEND initiative and portfolio review to drive efficiency and focus on cancer care.
- Visibility Gap Persists: Management suspended EBITDA guidance, citing uncertainty in timing and impact of cost and revenue cycle actions.
Business Overview
Myriad Genetics is a molecular diagnostics company specializing in genetic testing for hereditary cancer, prenatal health, and mental health. The company generates revenue by processing and analyzing patient samples to deliver actionable results to clinicians, with its business divided into three main segments: Cancer Care Continuum (hereditary cancer and oncology), Prenatal Health, and Mental Health (notably GeneSight, pharmacogenomic testing). Its core value proposition lies in leveraging clinical-grade genomics and AI to inform patient care and treatment decisions.
Performance Analysis
Second quarter revenue fell 11% year-over-year to $190.7 million, driven by a 1% decline in overall test volumes and a 9% decrease in average revenue per test. The headline decline masked underlying volume growth in the Cancer Care Continuum segment—up 6%—and Mental Health, up 4%, but was more than offset by a 9% drop in Prenatal Health volumes. Average revenue per test was heavily impacted by $11 million in unfavorable prior-period adjustments and increased payer denials, especially for hereditary cancer testing.
Gross margin compressed to 66.6%, down 460 basis points, reflecting both lower revenue per test and the adverse revenue adjustments. Adjusted operating expenses rose, as the company invested in commercial expansion, R&D, and new product launches, leading to an adjusted EPS loss of $0.25. Liquidity remains solid with $190 million in available capital, but the company has suspended EBITDA guidance due to uncertainty around the timing and impact of its cost initiatives and reimbursement recovery efforts.
- Hereditary Cancer Test Volume Strength: MyRisk hereditary cancer test volume grew 10%, but average revenue per test fell 15% due to payer friction.
- Prenatal Segment Weakness: Prenatal health revenue dropped 16%, with both volume and price under pressure amid competitive and execution challenges.
- Mental Health Stability: GeneSight revenue fell 3% despite volume growth, as a $4 million AR write-off obscured otherwise improving reimbursement trends.
Management’s revised 2026 revenue guidance is $770–790 million, a $90 million reduction, reflecting muted expectations for both volume and reimbursement improvement in the second half. The company does not expect new commercial hires or product launches to contribute materially until 2027.
Executive Commentary
"Mitigating the HCT average revenue per test pressure is one of our top priorities. We are executing a focused and comprehensive action plan to address it... We anticipate this initiative will produce meaningful measurable benefits to profitability including adjusted EBITDA in 2027 and beyond."
Sam Raha, President and Chief Executive Officer
"Our revised outlook takes a more conservative approach and assumes second half revenue is approximately in line with first half performance. The guidance also assumes no contribution from commercial team expansion initiatives or recent product launches despite the investments we've made in both areas."
Ben Wheeler, Chief Financial Officer
Strategic Positioning
1. Revenue Cycle and Reimbursement Optimization
Myriad is aggressively targeting payer friction through a multi-pronged approach: improving front-end coverage verification, leveraging AI for claim resolution, and increasing direct engagement with payers. The company is also integrating third-party medical record repositories to automate documentation and appeals. These actions are designed to restore predictability and reduce administrative burden, but management acknowledges that payer-driven denials remain a persistent industry-wide challenge.
2. Portfolio Rationalization and Capital Allocation
A rigorous portfolio review is underway to redirect capital toward the highest-value opportunities, with a clear emphasis on the Cancer Care Continuum. This could result in divestitures or deprioritization of underperforming assets, particularly in prenatal health, as management seeks to concentrate resources on scalable, high-margin segments.
3. Organizational Efficiency via ASCEND Initiative
Through the ASCEND initiative, supported by a leading professional services firm, Myriad aims to increase efficiency, productivity, and scalability across operations. This includes targeted cost reductions in revenue cycle management and broader process simplification. The company expects these changes to yield material EBITDA improvement starting in 2027, though the exact timing and magnitude remain uncertain.
4. Commercial and Product Innovation
Despite current headwinds, Myriad continues to invest in commercial expansion and product innovation. The launch of Prolaris Plus AI and expanded availability of Precise MRD (Minimal Residual Disease, a test for cancer recurrence monitoring) are positioned to drive future growth. Over 100 new account executives have been onboarded to support cancer care offerings, with meaningful volume impact expected in 2027.
5. Mental Health and Prenatal: Mixed Trajectory
Mental health demand remains robust, as evidenced by record provider adoption of GeneSight, but AR write-offs and payer behavior have masked underlying growth. The prenatal segment remains challenged, with new product FirstGene aiming to stabilize performance, though competitive and salesforce timing issues cloud near-term prospects.
Key Considerations
This quarter marks a strategic inflection point, as Myriad Genetics faces a convergence of payer headwinds and operational complexity while doubling down on its core cancer care franchise.
Key Considerations:
- Payer Denial Escalation: Select payers have increased automated denials and documentation demands, directly reducing test reimbursement and creating revenue unpredictability.
- Delayed Impact from Commercial Investments: Over 100 new sales hires and recent launches (Prolaris Plus AI, FirstGene) are not expected to contribute meaningfully until 2027, limiting near-term upside.
- Portfolio and Cost Structure in Flux: Ongoing portfolio review and the ASCEND initiative may lead to asset divestitures and structural cost reductions, but execution risk is high given the breadth of changes.
- Resilient Core Demand: Hereditary cancer and mental health test volumes remain strong, underscoring underlying clinical demand even as reimbursement lags.
Risks
Persistent payer-driven reimbursement friction, especially for hereditary cancer testing, remains the most significant near-term risk, with no guarantee of near-term resolution. Operational execution risk is elevated as Myriad undertakes simultaneous cost, portfolio, and commercial restructuring. Prenatal health remains structurally challenged, and further AR write-downs or delays in commercial ramp could pressure liquidity and margin recovery. Regulatory changes or broader industry shifts in payer practices could amplify these risks.
Forward Outlook
For Q3 2026, Myriad guided to:
- Revenue flat to slightly higher than Q2
- Continued pressure on average revenue per test, with no improvement assumed
For full-year 2026, management lowered guidance:
- Revenue: $770 to $790 million
- Gross margin: 66 to 67%
- Suspended adjusted EBITDA guidance due to timing and impact uncertainty of cost and revenue initiatives
Management emphasized:
- Assumptions are conservative, reflecting no near-term benefit from new sales hires or product launches
- ASCEND initiative and portfolio review are expected to yield material financial benefits in 2027 and beyond
Takeaways
Investors face a near-term visibility gap as Myriad Genetics navigates reimbursement headwinds and operational overhaul, but the company’s commitment to core cancer care and cost efficiency could drive a stronger, more focused business in 2027.
- Revenue Headwinds Are Structural: Payer friction is not a transient issue, and management’s actions are necessary but will take time to restore margin and predictability.
- Execution on Cost and Portfolio Initiatives Is Critical: Success of the ASCEND program and portfolio focus will determine whether Myriad can return to sustainable growth and profitability.
- Watch for Commercial Ramp and Product Uptake in 2027: The impact of new hires and recent launches is a key lever for future growth, but patience is required as benefits are unlikely in the next two quarters.
Conclusion
Myriad Genetics’ Q2 2026 results reflect a business at a crossroads: core demand is strong, but payer friction and prenatal weakness have forced a reset in expectations. The company’s multi-year transformation—anchored in cancer care, operational efficiency, and portfolio discipline—will be the main determinant of long-term shareholder value.
Industry Read-Through
Payer-driven revenue cycle friction is an industry-wide challenge for molecular diagnostics and laboratory services, not isolated to Myriad. The increased use of automated denials and documentation requirements by payers is likely to pressure reimbursement and revenue predictability across the sector, particularly for high-cost or high-volume molecular tests. Companies with diversified portfolios, scalable automation, and strong payer relationships will be best positioned to weather this environment. The move toward AI-enabled workflow and portfolio rationalization signals a broader industry shift toward operational discipline and clinical differentiation, as reimbursement headwinds become the new normal in diagnostics.